Clinical measurement of cellular DNA damage hypersensitivity in patients with DNA repair defects.
Cell division assay (CDA)
Clinical diagnosis
DNA repair deficiency disorders
Ionizing radiation sensitivity
Mitomycin C sensitivity
γ-H2AX
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
14 02 2022
14 02 2022
Historique:
received:
04
10
2021
accepted:
30
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
12
3
2022
Statut:
epublish
Résumé
DNA repair deficiency disorders are rare inherited diseases arising from pathogenic (disease-causing) variants in genes involved in DNA repair. There are no standardized diagnostic assays for the investigation of pathological significance of unknown variants in DNA repair genes. We hypothesized that our assays for measuring in vitro patient blood cell hypersensitivity to DNA-damaging agents can be used to establish the pathological significance of unknown variants in DNA repair genes. Six patients with variants in the DNA repair genes PRKDC (two siblings), DCLRE1C (two siblings), NBN, and MSH6 were included. Here, we used the cell division assay (CDA) and the γ-H2AX assay, which were both developed and clinically validated by us, to measure patient cell hypersensitivity in response to ionizing radiation, mitomycin C, cytarabine and doxorubicin. Radiation hypersensitivity was detected in the two patients with variants in the PRKDC gene (p < 0.0001 for both at 3.5 Gy), and the two patients with DCLRE1C variants (p < 0.0001 at 3.5 Gy for sibling 1 and p < 0.0001 at 1 Gy for sibling 2). The cells from the patients with the PRKDC variant were also deficient in removing γ-H2AX (p < 0.001). The cells from the patient with variants in the NBN gene were hypersensitive to mitomycin C (p = 0.0008) and deficient in both induction and removal of γ-H2AX in response to radiation. The combination of the CDA and the γ-H2AX assay is useful in investigating the significance of unknown variants in some DNA repair genes.
Sections du résumé
BACKGROUND
DNA repair deficiency disorders are rare inherited diseases arising from pathogenic (disease-causing) variants in genes involved in DNA repair. There are no standardized diagnostic assays for the investigation of pathological significance of unknown variants in DNA repair genes. We hypothesized that our assays for measuring in vitro patient blood cell hypersensitivity to DNA-damaging agents can be used to establish the pathological significance of unknown variants in DNA repair genes. Six patients with variants in the DNA repair genes PRKDC (two siblings), DCLRE1C (two siblings), NBN, and MSH6 were included. Here, we used the cell division assay (CDA) and the γ-H2AX assay, which were both developed and clinically validated by us, to measure patient cell hypersensitivity in response to ionizing radiation, mitomycin C, cytarabine and doxorubicin.
RESULTS
Radiation hypersensitivity was detected in the two patients with variants in the PRKDC gene (p < 0.0001 for both at 3.5 Gy), and the two patients with DCLRE1C variants (p < 0.0001 at 3.5 Gy for sibling 1 and p < 0.0001 at 1 Gy for sibling 2). The cells from the patients with the PRKDC variant were also deficient in removing γ-H2AX (p < 0.001). The cells from the patient with variants in the NBN gene were hypersensitive to mitomycin C (p = 0.0008) and deficient in both induction and removal of γ-H2AX in response to radiation.
CONCLUSIONS
The combination of the CDA and the γ-H2AX assay is useful in investigating the significance of unknown variants in some DNA repair genes.
Identifiants
pubmed: 35164800
doi: 10.1186/s13023-022-02199-8
pii: 10.1186/s13023-022-02199-8
pmc: PMC8842932
doi:
Substances chimiques
Histones
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
50Informations de copyright
© 2022. The Author(s).
Références
Hum Mol Genet. 2000 Mar 1;9(4):583-8
pubmed: 10699181
J Clin Invest. 2009 Jan;119(1):91-8
pubmed: 19075392
Cytometry B Clin Cytom. 2017 Nov;92(6):534-540
pubmed: 27060560
Prog Biophys Mol Biol. 2015 Mar;117(2-3):194-205
pubmed: 25550082
Genes Cells. 1999 Feb;4(2):77-85
pubmed: 10320474
Trends Cancer. 2017 Dec;3(12):840-856
pubmed: 29198440
Cytometry B Clin Cytom. 2021 May;100(3):370-376
pubmed: 32857894
Hum Genet. 2008 Sep;124(2):105-22
pubmed: 18709565
Mutat Res. 2013 Jul-Sep;753(1):24-40
pubmed: 23416207
Cytometry B Clin Cytom. 2018 Nov;94(6):946-949
pubmed: 29415368
EMBO J. 2008 Feb 20;27(4):589-605
pubmed: 18285820
Nucleic Acids Res. 2007;35(5):e36
pubmed: 17284459
Clin Biochem. 2016 May;49(7-8):566-72
pubmed: 26779995
Radiother Oncol. 2002 Mar;62(3):345-7
pubmed: 12175566
Nat Protoc. 2008;3(7):1187-93
pubmed: 18600224
DNA Repair (Amst). 2004 Aug-Sep;3(8-9):1187-96
pubmed: 15279807
DNA Repair (Amst). 2004 Aug-Sep;3(8-9):855-61
pubmed: 15279770
N Engl J Med. 2017 Nov 9;377(19):1868-1876
pubmed: 29117491
Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):510-6
pubmed: 19858715
EMBO J. 2014 Aug 1;33(15):1698-712
pubmed: 24966277
Biomolecules. 2015 Aug 20;5(3):1990-2002
pubmed: 26308066
Neoplasma. 2003;50(5):311-8
pubmed: 14628082
Eur J Dermatol. 2012 Jul-Aug;22(4):443-55
pubmed: 22436139